Summary: Nyxoah SA has appointed Maurits S. Boon, MD, who is acknowledged for his get the job done in hypoglossal nerve stimulation remedy to deal with obstructive snooze apnea, as chief clinical officer. Boon, from Thomas Jefferson University, contributed to Nyxoah’s Desire US trial, which shown a 70.8% reduction in the apnea-hypopnea index with the Genio procedure. His abilities will guidance Nyxoah’s US Food items and Drug Administration approval efforts and its mission to boost obstructive rest apnea affected person treatment.
Key Takeaways:
- Maurits S. Boon, MD has been appointed as the main health care officer at Nyxoah SA, where he will leverage his knowledge in hypoglossal nerve stimulation to enhance solutions for obstructive rest apnea.
- Boon was a contributor to Nyxoah’s Aspiration US pivotal study, which noted a 70.8% median reduction in the apnea-hypopnea index between individuals making use of the Genio procedure.
- Boon is dual board-qualified in otolaryngology – head and neck surgery, as effectively as rest medication, and he continues to be a element-time professor and vice chairman of education and learning at Thomas Jefferson College. He is internationally regarded for his function in slumber surgical treatment, particularly hypoglossal nerve stimulation techniques.
Nyxoah SA, maker of the CE-marked Genio neurostimulator for the treatment method of obstructive rest apnea, has appointed Maurits S. Boon, MD, as main clinical officer.
Boon joins Nyxoah from the Thomas Jefferson College, exactly where he will keep on component-time as a professor and vice chairman of education. He is twin board-qualified in otolaryngology – head and neck surgical procedures, as perfectly as snooze medication.
Boon is a single of two slumber surgeons with Jefferson Wellness to pioneer the use of hypoglossal nerve stimulation remedy and is internationally acknowledged as just one of the most knowledgeable surgeons undertaking hypoglossal nerve stimulation methods, in accordance to a release from Nyxoah. He has lectured worldwide on obstructive rest apnea, has several publications, and is co-editor of the 1st e-book on hypoglossal nerve stimulation.
Desire US Review Good results Supports New CMO’s Vision for Current market Enlargement
Nyxoah not too long ago introduced 12-thirty day period results of its Aspiration US pivotal study—which Boon participated in—designed to aid the marketing authorization of the Genio hypoglossal nerve stimulation procedure for obstructive slumber apnea in the United States. Topics shown a median 12-month apnea-hypopnea index (AHI) reduction of 70.8%, with similar AHI advancements in supine and non-supine sleeping positions.
“As an educational medical doctor who has committed my specialist profession to the care of people with sleep-disordered respiratory, I was privileged to take part in the Dream US pivotal trial. I was at first amazed by the final results I observed in my people and then similarly impressed by the info that were being lately documented. As this sort of, I am honored to have been made available a situation to be a part of Nyxoah at these an interesting time.
“Bilateral hypoglossal nerve stimulation with Genio has incredible likely, and I am thrilled to function with their proficient crew to make a significant effect on the lives of clients with obstructive snooze apnea,” states Boon in a release.
Nyxoah is now finalizing the fourth and remaining module submission in the premarket approval application to post for US Food stuff and Drug Administration acceptance.
“I could not be extra fired up to have Dr Boon join Nyxoah,” states Olivier Taelman, main government officer of Nyxoah in a launch. “He is one of the pioneers in hypoglossal nerve stimulation, and his determination to come to be Nyxoah’s chief medical officer demonstrates Genio’s capability to boost the lives of OSA individuals. Dr Boon will play a essential part as we prepare to enter the US industry and attain our mission of building sleep uncomplicated yet again.”
Picture caption: Maurits S. Boon, MD
Image credit score: Nyxoah SA
Leave a Reply